Biogen, Gilead could have beat-and-raise quarters, with Vertex and Incyte also doing well
Gilead Sciences' (GILD) $11.9 billion acquisition of Kite Pharma is paying off.
Gilead Sciences stock finally entered a new uptrend after underperforming biotech peers for nearly two years.
The biotech sector offers opportunity for stock investors.
Bluebird Bio's technical breakout following Gilead's acquisition of Kite Pharma could point to more upside ahead.
Biotech stocks jump this week on news of Gilead's $12 billion acquisition of Kite Pharma Inc.
Bullish chart patterns on biotech-related assets suggest that the bulls are in control of the momentum.
Juno Therapeutics shares continued their rally, but traders will be watching these key levels over the coming days.
A Monday biotech merger triggered a sector-wide advance that could lift junior biotech stocks to multi-year highs.
Bullish chart patterns on key biotech names are presenting traders with the best risk/reward setup of 2017.